Photo od Ahmed Kotb
from daiichisankyo.us
Jun 22, 2025, 11:29
Ahmed Kotb: Choosing the Right DOAC For Your Patient?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“Choosing the right DOAC for your patient?
anticoagulant choice based on clinical profiles”
Elderly/Frail- Apixaban, Edoxaban
Obese -Apixaban or Rivaroxaban
CKD Apixaban, Edoxaban 30mg
GI Bleed Risk-Apixaban
Compliance issues- Edoxaban, Rivaroxaban
You can explore more detailed, evidence-based insights on individualized anticoagulant therapy at Hemostasis Today, your source for expert-guided approaches in thrombosis and hemostasis.
-
Nov 15, 2025, 15:47Shannon Farmer: Congratulations to Susan Goobie and Colleagues on Publication of Their Important Study
-
Nov 15, 2025, 15:46Fotios Barkas: Explore the Latest Articles From the Journal of Atherosclerosis Prevention and Treatment!
-
Nov 15, 2025, 15:45Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
-
Nov 15, 2025, 15:42Haroun Gajraj Thanks Enric Roche for Demonstrating the Piston Effect
-
Nov 15, 2025, 15:41Thrombectomy Rates Rise 700% Nationwide
-
Nov 15, 2025, 15:41Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
-
Nov 15, 2025, 15:40Bruno Lima: I Owe a Lot of My Career to Dr. Brad Maron
-
Nov 15, 2025, 15:39Ramesh Balasubramanian: Future of Hematology is Encouraging. Striving Towards More Cure for the Dreaded Cancer
-
Nov 15, 2025, 15:37Atrial Fibrillation Increases the Risk of Stroke by Up to Fivefold Due to Clot Formation in the Atria